Cargando…
Bexarotene combined with lapatinib for the treatment of Cushing’s disease: evidence based on drug repositioning and experimental confirmation
Autores principales: | Yu, Haoying, Ren, Shuyue, Wang, Jingrong, Lv, Tingting, Sun, Lan, Du, Guanhua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456421/ https://www.ncbi.nlm.nih.gov/pubmed/32862196 http://dx.doi.org/10.1038/s41392-020-00284-7 |
Ejemplares similares
-
A Novel Co-Crystal of Bexarotene and Ligustrazine Improves Pharmacokinetics and Tissue Distribution of Bexarotene in SD Rats
por: Ren, Shuyue, et al.
Publicado: (2020) -
Circular RNAs: Promising Molecular Biomarkers of Human Aging-Related Diseases via Functioning as an miRNA Sponge
por: Ren, Shuyue, et al.
Publicado: (2020) -
Targeting Myadm to Intervene Pulmonary Hypertension on Rats Before Pregnancy Alleviates the Effect on Their Offspring’s Cardiac-Cerebral Systems
por: Wang, Jingrong, et al.
Publicado: (2022) -
Tamoxifen Exerts Anticancer Effects on Pituitary Adenoma Progression via Inducing Cell Apoptosis and Inhibiting Cell Migration
por: Lv, Tingting, et al.
Publicado: (2022) -
Comparison of the Efficacy and Safety of Bexarotene and Photo(Chemo)Therapy Combination Therapy and Bexarotene Monotherapy for Cutaneous T-Cell Lymphoma
por: Morita, Akimichi, et al.
Publicado: (2022)